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1  | INTRODUC TION
Long QT syndrome (LQTS) causes sudden cardiac death due to ven‐
tricular arrhythmias such as Torsades de Pointes (TdP) or ventricular 
fibrillation (VF). Functional 2:1 atrioventricular block (AVB), one of the 
malignant forms of arrhythmias in LQTS, is most frequently observed 
in neonates with LQTS type 2 or 3.1 In LQTS type 3 (LQT3), a gain‐of‐
function mutation is observed in the SCN5A gene encoding the α‐sub‐
unit of the cardiac voltage‐dependent sodium channel. Mexiletine, a 
sodium channel blocker, is considered to be effective for patients with 
LQT3.2 Intravenous mexiletine for arrhythmias is commercially avail‐
able and is covered by the health insurance system in Japan. We report 
a neonatal LQT3 case that underwent a mexiletine infusion challenge 
test for the diagnosis and prediction of its efficacy.
2  | C A SE REPORT
A female infant was delivered at a gestational age of 37 weeks with 
a birth weight of 3,068 g. The results of fetal nonstress test and fetal 
echocardiogram were normal. On the second day after birth, the 
patient presented with transient bradycardia (70 bpm). There were 
no abnormalities in echocardiographic evaluation. The electrocar‐
diogram on day 7 showed a prolongation of the QTc (QTcB (QT cor‐
rection with Bazett formula) 560 ms, and QTcF (QT correction with 
Friedericia formula) 541 ms), 2:1 AVB (RR interval, 810 ms), and 
late‐onset type of T waves (Figure 1). No ventricular tachycardia 
was observed even with bradycardia. At an age of 20 days, a mexi‐
letine infusion challenge test was performed. Mexiletine (2 mg/
kg) was infused intravenously for 10 minutes, and the 12‐lead ECG 
was continuously recorded from before the infusion until 2 hours 
after the infusion. Changes in the ECG parameters (RR and QT in‐
tervals) were analyzed in lead V5. Shortening of the QTc (QTcB 
by 49 ms, and QTcF by 45 ms) without any arrhythmic events was 
observed 10 minutes after the infusion, and 1:1 atrioventricular 
conduction was achieved 120 minutes after the infusion (Figure 2). 
One day after the infusion challenge test, oral administration of 
mexiletine was initiated (6 mg/kg/day). Mexiletine was gradually 
increased to 15 mg/kg/day in three divided doses. During the 
follow‐up, a 12‐lead ECG and Holter monitoring were repeatedly 
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Abstract
For applying a genotype‐based treatment in neonatal long QT syndrome (LQTS), 
early detection of the genotype becomes an important issue. We report a case of a 
neonate with LQTS type 3 that presented with 2:1 atrioventricular block and under‐
went a mexiletine infusion challenge test, and achieved shortening of the QTc and 
1:1 atrioventricular conduction. The mexiletine infusion challenge test was helpful to 
make an early detection of the genotype of the LQTS and predicted the drug efficacy 
in a neonatal patient.
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recorded. The QTc remained in the normal range and 1:1 atrio‐
ventricular conduction was maintained under the oral mexiletine 
therapy as of 15 months (Figure 3). No ventricular tachycardia has 
been observed.
Genetic testing revealed an SCN5A gene mutation (Val1763Met), 
which is a pathogenic mutation of LQT3.3 No mutations in the SCN5A 
gene were found in her parents or brother.
3  | DISCUSSION
For an effective and safe genotype‐based treatment choice, an 
early diagnosis is especially important in patients with lethal ar‐
rhythmias in LQTS. Mexiletine has been shown to be effective 
in preventing TdP and VF in LQT3.2 The use of the lidocaine 
infusion test for an early diagnosis has been reported.4 Since 
an oral mexiletine administration is generally chosen as the 
maintenance therapy for LQT3, a mexiletine infusion challenge 
test for a diagnosis and the prediction of the efficacy would 
be reasonable. Although there have been reports of mexiletine 
challenge tests in older children and adults, 5,6to the best of 
our knowledge, this case is the first report of an intravenous 
mexiletine challenge test in a neonate. According to Schwarts5, 
half of the daily dose of oral mexiletine should be administered 
F I G U R E  1   Twelve‐lead electrocardiogram on day 7 shows 2:1 AVB, prolongation of the QT interval (QT of 502 ms, QTcB (QT correction 
with Bazett formula) 560 ms, and QTcF (QT correction with Friedericia formula) 541 ms) and late‐onset type T waves
F I G U R E  2   A, Before the infusion, RR 750 ms, QT 464 ms, QTcB 
536 ms, and QTcF 511 ms. B, Ten minutes after the infusion, RR 
766 ms, QT 426 ms, QTcB 487 ms, and QTcF 466 ms. C, Two hours 
after the infusion, RR 454 ms, QT 322 ms, QTcB 478 ms, and QTcF 
419 ms
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and the ECG should be followed for 2 hours. If the QTcB short‐
ens by more than 40 ms and there are no arrhythmic events, 
mexiletine is judged to be effective. In the present case, we 
considered that the oral administration of mexiletine could be 
efficacious because the QTc shortened and 1:1 atrioventricular 
conduction was restored without any ventricular arrhythmias 
2 hours after the test, and therefore, the patient underwent 
oral mexiletine therapy.
Because mexiletine has minimal side effects involving prolon‐
gation of the QT interval, and also has the effect of reducing the 
dispersion of the repolarization and prevents TdP, the mexiletine 
challenge test can be performed safely with a low risk of pro‐ar‐
rhythmic events in LQTS patients.6 Mexiletine has the potential 
of shortening the QT interval in any type of LQTS by inhibiting 
the late sodium current. Theoretically, mexiletine could also be 
effective in many LQT2 neonates with 2:1 atrioventricular block at 
some level, and how to distinguish them might become a problem. 
Although the optimal cutoff point of the degree of shortening of 
the QT interval for differentiating LQT3 from the other types of 
LQTS in neonates is still not clear, the degree of the shortening of 
the QT interval might be greater in LQT3 than LQT2. While there 
are some limitations, a mexiletine infusion challenge test in neo‐
nates may be useful for the detection of LQT3.
4  | CONCLUSION
The mexiletine infusion challenge test was effective for the predic‐
tion of the drug efficacy and for an early diagnosis in a neonate with 
a malignant form of LQT3.
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